October Bulletin
Issue 61
Community Notices | News | Jobs | Funding | Events
Community Notices
October Seminar
Next Marble Center seminar is on Monday October 18th, 4-5pm, with a research update by Drs. Natalie Boehnke and Joelle Straehla of the Hammond lab on “Studying nanoparticle delivery through the lens of omics.” Following the talk, we will host a corporate overview by Dr. Chris Pacheco, General Partner at Alloy Therapeutics’ in-house company creation studio (82VS).
The seminar will be hybrid in format. For remote access via Zoom, please register here. Following the seminar, please join us for an outdoor social with food and soft drinks at the Hockfield Court (starting at 5pm).
In the News
Happy National Nano Day!
National Nanotechnology Day is an annual celebration featuring a series of community-led events and activities on or around October 9 to help raise awareness of nanotechnology, how it is currently used in products that enrich our daily lives, and the challenges and opportunities it holds for the future. Check out our sneak peek of IAMNano, our new industry initiative bringing our research community and industry together to solve grand challenges in oncology and more!
Elicio Therapeutics Announces First Patient Dosed in the ELI-002 (AMPLIFY-201) study in KRAS-Driven Cancers
(Global Newswire) Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, announced on October 6th that the first patient has been dosed with ELI-002, an investigational lymph node-targeted therapeutic vaccine, by Shubham Pant, M.D. at MD Anderson as part of a Phase 1/2 (AMPLIFY-201) study evaluating its safety and efficacy as a treatment for patients with KRAS-driven tumors who have minimal residual tumor cells following surgery to remove the tumor. The trial is expected to enroll patients with mKRAS+ solid tumors, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and other solid tumors. ELI-002 is an Amphiphile (AMP) KRAS investigational therapeutic vaccine containing AMP mKRAS peptides and a proprietary AMP CpG adjuvant, administered subcutaneously. Read more…
Location matters as companies get their innovation mojo back
(Beth Stackpole, MIT Sloan) The COVID-19 pandemic upended life as we know it, putting many long-standing business assumptions to the test. Now as the world tries to envision a post-pandemic future, experts in innovation say place-based ecosystems are more relevant than ever. Despite myriad challenges from lockdowns to interruptions of global supply chains, the idea that proximity helps inspire novel ideas and produce disruptive products has endured. In an innovation ecosystem, organizations engage with a diverse range of external players to accelerate their innovation cycles, a phenomenon that has led to geographic hotspots for innovation from Silicon Valley and New York, to Shenzhen, China and Cape Town, South Africa. Read more…
3 Questions: Paula Hammond and Tim Jamison on graduate student advising and mentoring
Paula Hammond and Tim Jamison (Credits: Gretchen Ertl (Hammond), Justin Knight (Jamison))
(MIT News) committee co-chairs Paula Hammond (Institute Professor and head of the Department of Chemical Engineering) and Tim Jamison (the Robert R. Taylor Professor of Chemistry and associate provost) discuss the committee’s origin and the work already underway across campus, and offer insight into the future of advising and mentoring at MIT. Read more…
Community news!
Jobs
Assistant Director of Research Development, Grainger College of Engineering at the University of Illinois at Urbana-Champaign
Engineering Administration at The Grainger College of Engineering seeks applicants for the position of Assistant Director for Research Development. Reporting to the Assistant Dean for Research, the Assistant Director for Research Development is responsible for research development, proposal preparation, and project initiation needs for large, externally-funded opportunities such as center and institutes in The Grainger College of Engineering and will execute special programs as defined by the Assistant Dean for Research. Read more…
Scientist, LNP Discovery Formulations, Beam Therapeutics.
Beam Therapeutics is seeking a scientist with expertise in nanoparticle delivery to conduct the LNP formulation and characterization of LNPs targeting extrahepatic tissues. The ideal candidate will have experience with the formulation and testing of lipid nanoparticle formulations and be excited to work in a fast-paced and multi-disciplinary environment. Read more…
Scientist, LNP Formulation, Tessera.
The successful candidate will work both independently and as part of a rapidly growing formulations team to develop new lipid nanoparticle to support key proof of concept studies with Tessera’s novel payloads. The ideal candidate will have experience with formulation optimization, characterization and downstream assays for a variety of novel payloads. The Formulation Scientist will work closely with other individuals from delivery biology, chemistry, analytics and platform teams at Tessera. In addition, the candidate will contribute to high level planning for the LNP group and represent the formulation team in cross functional discussions within Tessera. Read more…
Funding opportunities
| Funding Source | Grant ID | Deadline | NSF Biosensing RFP | PD 20-7909 | N/A |
|---|---|---|
| NIH/NCI: Toward Translation of Nanotechnology Cancer Interventions | PAR-20-116 | November 18, 2021 |
